- Waldenström Macroglobulinemia
- Melanoma
- Bladder Cancer
- Brain Cancer
- Breast Cancer
- Childhood Cancers
- Gastric Cancer
- Gynecologic Cancer
- Head & Neck Cancer
- Immunotherapy
- Kidney Cancer
- Leukemia
- Liver Cancer
- Lung Cancer
- Lymphoma Cancer
- Mesothelioma
- MPN
- MDS
- Myeloma
- Prostate Cancer
- Rare Cancers
- Sarcoma
- Skin Cancer
- Testicular Cancer
- Thyroid Cancer
Liver Cancer Awareness Month: What You Need to Know
For Liver Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.
For Liver Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space:
- As immunotherapies emerge in the treatment of liver cancer, experts examine whether two or more is better than one.
- Taking aspirin was found to improve liver function and extend survival among patients with hepatocellular carcinoma — the most common primary liver cancer.
- Researchers have found a biomarker that may help to determine which patients with hepatocellular carcinoma will respond to treatment with Nexavar, leading to more individualized treatment options.
- The president and founder of Blue Faery: The Adrienne Wilson Liver Cancer Association discussed new initiatives and what’s on the horizon in the treatment of liver cancer.
- While advances have been made in the treatment landscape of hepatocellular carcinoma, researchers are now looking into the optimal sequence for which patients should be treated.
Creating a Charity 8 Days After a Rare Cancer Diagnosis: Dying Defiantly Founder Shares His Story
December 8th 2022After Marshall Morris was diagnosed with a rare cancer and given only six months to live, he created a charity that empowers people with terminal illness and provides them with counseling and support.
Listen
Adding a Novel Agent to Standard of Care May Improve Survival in Liver Cancer
October 13th 2023Adding TPST-1120 to the standard of care for the treatment of unresectable or metastatic hepatocellular carcinoma, a type of liver cancer, improved progression-free survival and overall survival in a phase 1b/2 clinical study.
Read More
